DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
LARSUCOSTEROL
2
Small molecule
Investigational
Unknown
Unknown
Cholangitis, Sclerosing; Hepatitis, Alcoholic; Severe Acute Respiratory Syndrome
Unknown
LARSUCOSTEROL
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C27H46O5S
Molecular Weight:
482.73
AlogP:
6.33
PSA:
83.83
HBD:
2.0
HBA:
#RotB:
7.0
Source:
TOREFORANT
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Histamine H4 receptor antagonist
TOREFORANT
×
Maximum Phase:
2
First Approval:
None
UNII:
U6LA7G393X
Molecule Type:
Small molecule
Molecular Formula:
C23H32N6
Molecular Weight:
392.55
AlogP:
4.48
PSA:
69.73
HBD:
2.0
HBA:
#RotB:
6.0
Source:
AVAGACESTAT
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Gamma-secretase inhibitor
AVAGACESTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
TQ44WWY45Q
Molecule Type:
Small molecule
Molecular Formula:
C20H17ClF4N4O4S
Molecular Weight:
520.89
AlogP:
3.92
PSA:
119.39
HBD:
1.0
HBA:
#RotB:
9.0
Source:
PILARALISIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Lymphoma; Neoplasms; Endometrial Neoplasms
PI3-kinase class I inhibitor
PILARALISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
60ES45KTMK
Molecule Type:
Small molecule
Molecular Formula:
C25H25ClN6O4S
Molecular Weight:
541.03
AlogP:
4.51
PSA:
148.33
HBD:
4.0
HBA:
#RotB:
8.0
Source:
AMMONIUM TRICHLOROTELLURATE
2
Small molecule
Investigational
Unknown
Unknown
Macular Degeneration; Alopecia; Condylomata Acuminata; Dermatitis, Atopic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Psoriasis
Unknown
AMMONIUM TRICHLOROTELLURATE
×
Maximum Phase:
2
First Approval:
None
UNII:
708681952A
Molecule Type:
Small molecule
Molecular Formula:
C2H8Cl3NO2Te
Molecular Weight:
312.05
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
BMS-646256
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BMS-646256
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROLIPRAM
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major; Huntington Disease; Nervous System Diseases; Multiple Sclerosis
Unknown
ROLIPRAM
×
Maximum Phase:
2
First Approval:
None
UNII:
K676NL63N7
Molecule Type:
Small molecule
Molecular Formula:
C16H21NO3
Molecular Weight:
275.35
AlogP:
2.62
PSA:
47.56
HBD:
1.0
HBA:
#RotB:
4.0
Source:
SAR-113945
2
Small molecule
Investigational
Unknown
Unknown
Osteoarthritis
Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor
SAR-113945
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LT-NS001
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LT-NS001
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOFIMILAST
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibitor
TOFIMILAST
×
Maximum Phase:
2
First Approval:
None
UNII:
5D7022962A
Molecule Type:
Small molecule
Molecular Formula:
C18H21N5S
Molecular Weight:
339.47
AlogP:
4.1
PSA:
48.53
HBD:
0.0
HBA:
#RotB:
3.0
Source:
LOMETREXOL
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Lung Neoplasms
Unknown
LOMETREXOL
×
Maximum Phase:
2
First Approval:
None
UNII:
6P3AVY8A7Q
Molecule Type:
Small molecule
Molecular Formula:
C21H25N5O6
Molecular Weight:
443.46
AlogP:
0.62
PSA:
187.5
HBD:
6.0
HBA:
#RotB:
9.0
Source:
AZD6765
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
AZD6765
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CIPARGAMIN
2
Small molecule
Investigational
Unknown
Unknown
Malaria, Falciparum; Malaria
P-type ATPase inhibitor
CIPARGAMIN
×
Maximum Phase:
2
First Approval:
None
UNII:
Z7Q4FWA04P
Molecule Type:
Small molecule
Molecular Formula:
C19H14Cl2FN3O
Molecular Weight:
390.25
AlogP:
4.34
PSA:
56.92
HBD:
3.0
HBA:
#RotB:
0.0
Source:
INO-1001
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
INO-1001
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CENERIMOD
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Lupus Erythematosus, Systemic
Sphingosine 1-phosphate receptor Edg-1 modulator
CENERIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
Y333RS1786
Molecule Type:
Small molecule
Molecular Formula:
C25H31N3O5
Molecular Weight:
453.54
AlogP:
4.07
PSA:
110.73
HBD:
2.0
HBA:
#RotB:
9.0
Source:
TIRABRUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Sjogren's Syndrome; Urticaria
Tyrosine-protein kinase BTK inhibitor
TIRABRUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
LXG44NDL2T
Molecule Type:
Small molecule
Molecular Formula:
C25H22N6O3
Molecular Weight:
454.49
AlogP:
2.75
PSA:
108.27
HBD:
1.0
HBA:
#RotB:
4.0
Source:
CILUPREVIR
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Hepatitis C virus serine protease, NS3/NS4A inhibitor
CILUPREVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
75C8DU40T0
Molecule Type:
Small molecule
Molecular Formula:
C40H50N6O8S
Molecular Weight:
774.94
AlogP:
6.05
PSA:
181.31
HBD:
4.0
HBA:
#RotB:
9.0
Source:
ILACIRNON
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerulosclerosis, Focal Segmental
C-C chemokine receptor type 2 antagonist
ILACIRNON
×
Maximum Phase:
2
First Approval:
None
UNII:
380F68J5PH
Molecule Type:
Small molecule
Molecular Formula:
C20H13ClF3N5O3S
Molecular Weight:
495.87
AlogP:
4.37
PSA:
117.7
HBD:
2.0
HBA:
#RotB:
5.0
Source:
KP-1461
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
DNA disrupting agent
KP-1461
×
Maximum Phase:
2
First Approval:
None
UNII:
3PEN569TJP
Molecule Type:
Small molecule
Molecular Formula:
C16H28N4O6
Molecular Weight:
372.42
AlogP:
0.49
PSA:
132.72
HBD:
4.0
HBA:
#RotB:
8.0
Source:
PEXACERFONT
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major; Anxiety Disorders; Irritable Bowel Syndrome
Corticotropin releasing factor receptor 1 antagonist
PEXACERFONT
×
Maximum Phase:
2
First Approval:
None
UNII:
LF1VBG4ZUK
Molecule Type:
Small molecule
Molecular Formula:
C18H24N6O
Molecular Weight:
340.43
AlogP:
3.33
PSA:
77.23
HBD:
1.0
HBA:
#RotB:
5.0
Source:
EXEPORFINIUM
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
EXEPORFINIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
R41ECT47G6
Molecule Type:
Small molecule
Molecular Formula:
C44H50N6O2+2
Molecular Weight:
694.92
AlogP:
8.94
PSA:
75.82
HBD:
2.0
HBA:
#RotB:
12.0
Source:
CC-11050
2
Small molecule
Investigational
Unknown
Unknown
Lupus Erythematosus, Cutaneous; Tuberculosis
Phosphodiesterase 4 inhibitor
CC-11050
×
Maximum Phase:
2
First Approval:
None
UNII:
1Z08G7438A
Molecule Type:
Small molecule
Molecular Formula:
C24H28N2O6S
Molecular Weight:
472.56
AlogP:
3.18
PSA:
102.01
HBD:
1.0
HBA:
#RotB:
9.0
Source:
BLX-028914
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BLX-028914
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LFF-571
2
Small molecule
Investigational
Unknown
Unknown
Clostridium Infections
Unknown
LFF-571
×
Maximum Phase:
2
First Approval:
None
UNII:
W7AUL2R95Z
Molecule Type:
Small molecule
Molecular Formula:
C60H63N13O13S6
Molecular Weight:
1366.64
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GLUCOSAMINE SULFATE POTASSIUM CHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GLUCOSAMINE SULFATE POTASSIUM CHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
15VQ11I66N
Molecule Type:
Small molecule
Molecular Formula:
C12H28Cl2K2N2O14S
Molecular Weight:
605.53
AlogP:
-3.25
PSA:
116.17
HBD:
5.0
HBA:
#RotB:
1.0
Source:
PIXANTRONE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms
DNA cross-linking agent
PIXANTRONE
×
Maximum Phase:
2
First Approval:
None
UNII:
F5SXN2KNMR
Molecule Type:
Small molecule
Molecular Formula:
C17H19N5O2
Molecular Weight:
325.37
AlogP:
0.6
PSA:
123.13
HBD:
4.0
HBA:
#RotB:
6.0
Source:
ATEVIRDINE MESYLATE
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
ATEVIRDINE MESYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
N24015WC6D
Molecule Type:
Small molecule
Molecular Formula:
C21H25N5O2
Molecular Weight:
379.46
AlogP:
2.97
PSA:
73.49
HBD:
2.0
HBA:
#RotB:
5.0
Source:
TENOFOVIR EXALIDEX
2
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Communicable Diseases
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
TENOFOVIR EXALIDEX
×
Maximum Phase:
2
First Approval:
None
UNII:
K7J545MEMA
Molecule Type:
Small molecule
Molecular Formula:
C28H52N5O5P
Molecular Weight:
569.73
AlogP:
6.86
PSA:
134.61
HBD:
2.0
HBA:
#RotB:
25.0
Source:
GSK239512
2
Small molecule
Investigational
Unknown
Unknown
Dementia; Multiple Sclerosis; Alzheimer Disease; Multiple Sclerosis, Relapsing-Remitting; Schizophrenia
Histamine H3 receptor antagonist
GSK239512
×
Maximum Phase:
2
First Approval:
None
UNII:
4I7U5C459M
Molecule Type:
Small molecule
Molecular Formula:
C23H27N3O2
Molecular Weight:
377.49
AlogP:
3.95
PSA:
45.67
HBD:
0.0
HBA:
#RotB:
4.0
Source:
LADARIXIN
2
Small molecule
Investigational
Unknown
Unknown
Pemphigoid, Bullous; Diabetes Mellitus, Type 1
Interleukin-8 receptor A modulator
LADARIXIN
×
Maximum Phase:
2
First Approval:
None
UNII:
DEH7Q6472O
Molecule Type:
Small molecule
Molecular Formula:
C11H12F3NO6S2
Molecular Weight:
375.35
AlogP:
1.09
PSA:
106.61
HBD:
1.0
HBA:
#RotB:
5.0
Source:
SIVIFENE
2
Small molecule
Investigational
Unknown
Unknown
Lymphoproliferative Disorders; Sarcoma, Kaposi; Cervical Intraepithelial Neoplasia
Unknown
SIVIFENE
×
Maximum Phase:
2
First Approval:
None
UNII:
XAV05295I5
Molecule Type:
Small molecule
Molecular Formula:
C19H14N4O6
Molecular Weight:
394.34
AlogP:
3.78
PSA:
151.13
HBD:
3.0
HBA:
#RotB:
6.0
Source:
FIRSOCOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Non-alcoholic Fatty Liver Disease
Acetyl-CoA carboxylase negative allosteric modulator
FIRSOCOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
XE10NJQ95M
Molecule Type:
Small molecule
Molecular Formula:
C28H31N3O8S
Molecular Weight:
569.64
AlogP:
3.95
PSA:
135.02
HBD:
1.0
HBA:
#RotB:
9.0
Source:
ZSTK-474
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
PI3-kinase class I inhibitor
ZSTK-474
×
Maximum Phase:
2
First Approval:
None
UNII:
K0068GK39A
Molecule Type:
Small molecule
Molecular Formula:
C23H17NOS
Molecular Weight:
355.46
AlogP:
6.25
PSA:
32.59
HBD:
1.0
HBA:
#RotB:
1.0
Source:
DU 125530
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder
Serotonin 1a (5-HT1a) receptor antagonist
DU 125530
×
Maximum Phase:
2
First Approval:
None
UNII:
ZB05V621UD
Molecule Type:
Small molecule
Molecular Formula:
C23H26ClN3O5S
Molecular Weight:
492.0
AlogP:
2.86
PSA:
79.39
HBD:
0.0
HBA:
#RotB:
6.0
Source:
SOLCITINIB
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative; Lupus Erythematosus, Systemic; Psoriasis
Tyrosine-protein kinase JAK1 inhibitor
SOLCITINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
3V7GQ1260K
Molecule Type:
Small molecule
Molecular Formula:
C22H23N5O2
Molecular Weight:
389.46
AlogP:
3.23
PSA:
79.6
HBD:
1.0
HBA:
#RotB:
4.0
Source:
1
2
…
103
104
105
106
107
108
109
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA